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Abstract. With its significant contribution to cancer mortality 
globally, advanced colorectal cancer (CRC) requires new 
treatment strategies. However, despite recent good results for 
mismatch repair (MMR)‑deficient CRC and other malignan‑
cies, such as melanoma, the vast majority of MMR‑proficient 
CRCs are resistant to checkpoint inhibitor (CKI) therapy. 
MMR‑proficient CRCs commonly develop from precursor 
adenomas with enhanced Wnt‑signalling due to adenomatous 
polyposis coli (APC) mutations. In melanomas with enhanced 
Wnt signalling due to stabilized β‑catenin, immune anergy 
and resistance to CKI therapy has been observed, which is 
dependent on micro‑environmental myelomonocytic (MM) 
cell depletion in melanoma models. However, MM popula‑
tions of colorectal adenomas or CRC have not been studied. 
To characterize resident intestinal MM cell populations during 
the early stages of tumorigenesis, the present study utilized 
the ApcMin/+ mouse as a model of MMR‑proficient CRC, using 
enhanced green fluorescent protein (EGFP) expression in 
the mouse lysozyme (M‑lys)lys‑EGFP/+ mouse as a pan‑myelo‑
monocytic cell marker and a panel of murine macrophage 
surface markers. Total intestinal lamina propria mononuclear 
cell (LPMNC) numbers significantly decreased with age 
(2.32±1.39x107 [n=4] at 33 days of age vs. 1.06±0.24x107 [n=8] 
at 109 days of age) during intestinal adenoma development 
in ApcMin/+ mice (P=0.05; unpaired Student's t‑test), but not 
in wild‑type littermates (P=0.35). Decreased total LPMNC 
numbers were associated with atrophy of intestinal lymphoid 
follicles and the absence of MM/lymphoid cell aggregates 
in ApcMin/+ mouse intestine, but not spleen, compared with 
wild‑type mice. Furthermore, during the early stage of intes‑
tinal adenoma development, there was a two‑fold reduction 
of M‑lys expressing cells (P=0.05) and four‑fold reduction 
of ER‑HR3 (macrophage sub‑set) expressing cells (P=0.05; 
two tailed Mann‑Whitney U test) in mice with reduced total 
intestinal LPMNCs (n=3). Further studies are necessary to 
determine the relevance of these findings to immune‑surveil‑
lance of colorectal adenomas or MMR‑proficient CRC CKI 
therapy resistance.
Introduction
Colorectal cancer (CRC), which accounts for nearly a million 
global deaths each year, remains a major cause of cancer 
mortality due to the limited efficacy of currently available 
systemic treatment for advanced disease (1). Consequently, 
improved understanding of the disease is required to further opti‑
mize systemic treatment strategies including immunotherapy. 
CRC is known to develop from intestinal epithelium following 
progressive accumulation of genetic alterations, which include 
mutations of the adenomatous polyposis coli (APC) gene (2). 
In the highly evolutionary conserved canonical Wnt signalling 
pathway, APC is known to target β‑catenin for cytoplasmic 
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degradation, thus preventing its nuclear translocation to 
promote tumorigenesis (3). Most sporadic CRCs are thought to 
acquire APC mutations as an early event during tumorigenesis, 
prior to the development of adenomas (4). Furthermore, patients 
with familial adenomatous polyposis (FAP) carry a germ‑line 
APC mutation, which predisposes the individual to intestinal 
adenomas and CRC (5). The ApcMin/+ mouse is a model of FAP 
that possess a germline heterozygous Δ850 Apc mutation (6). 
Such mice develop predominantly small intestinal adenomas 
and die at ~130 days of age from the intestinal adenoma 
burden (6). In addition, haematopoietic defects, including the 
development of generalized atrophy of lymphoid tissue, occur 
during the early stages of intestinal tumorigenesis at ~80 days 
of age (7), while myeloid defects have been reported at an 
advanced age in the ApcMin/+ mouse and another mouse model 
that is haplo‑insufficient for Apc (8,9).
Over the past decade, immune checkpoint inhibitor (CKI) 
therapy including targeting programmed cell death protein‑1 
(PD‑1), has emerged as an effective therapeutic strategy against 
several types of cancer, such as lung, melanoma and renal cell 
cancer (10). More recently, CKI therapy has been shown to be 
effective for the mismatch repair (MMR)‑deficient or micro‑
satellite instability (MSI)‑high subset of various malignancies, 
including CRC (11,12). However, this strategy has proven ineffec‑
tive so far in the management of the majority of MMR‑proficient 
CRC that represent >90% of sporadic CRCs (13). For mela‑
noma, higher neoantigen burden (14) and a greater extent of 
T lymphocyte infiltration (15) are correlated with enhanced 
responses to PD‑1 inhibition. However, T lymphocyte and MM 
cell infiltration have been inversely correlated with enhanced 
β‑catenin pathway signalling in melanoma (16). Furthermore, 
a study in autochthonous mouse melanoma models with consti‑
tutive β‑catenin signalling has demonstrated the dependence 
of T lymphocyte infiltration on the MM cell population (16). 
Therefore, characterization of the intestinal MM cell population 
during intestinal adenoma development in the ApcMin/+ model 
could yield insight into any early MM population changes asso‑
ciated with enhanced Wnt signalling.
A review on MM cells highlighted their heterogeneity, 
with no pan‑MM cell marker defined, which has compounded 
previous studies on MM cell populations (17). However, a mouse 
with EGFP knocked into the mouse‑lysozyme (M‑lys) locus 
by homologous recombination (M‑lyslys‑EGFP/lys‑EGFP) 
was previously generated, which utilizes EGFP expression 
to facilitate studies on murine MM cells (18). In this model, 
EGFP fluorescence has been observed in multiple surface 
marker‑defined peripheral MM sub‑populations (18). The 
present study had two aims. First, to determine if there is 
reduction of the total resident intestinal LPMNC popula‑
tion during the early stage of intestinal tumorigenesis. 
Furthermore, utilizing ApcMin/+ and wild‑type mice bred onto 
the M‑Lyslys‑EGFP/+ background, it was investigated if there is a 
reduction in the resident intestinal MM cell population during 
the early stage of intestinal tumorigenesis.
Materials and methods
Mice. C57BL/6J and C57BL/6J‑ApcMin/+ mice were obtained from 
The Jackson Laboratory. C57BL/6J/Sv129‑M‑lyslys‑EGFP/lys‑EGFP 
mice (18) were obtained from Albert Einstein College of 
Medicine. All mice were bred in‑house, kept under isolator 
conditions at temperatures between 19 and 23˚C on a 12‑h 
light‑dark cycle. They were pathogen‑free by regular bacte‑
riological and serological testing. Relative humidity was kept 
between 45 and 55%. The mice were fed on mouse complete 
maintenance diet with free access to food and water. For 
the experiments described here, the following mice were 
utilized: Apc+/+M‑Lys+/+ (n=20), ApcMin/+M‑Lys+/+ (n=23), 
Apc+/+M‑Lyslys‑EGFP/+ (n=9) And ApcMin/+M‑Lyslys‑EGFP/+ (n=12).
Mouse breeding and genotyping. Apc+/+ and ApcMin/+ mice 
on the M‑Lyslys+/+ background were obtained by mating male 
ApcMin/+M‑Lyslys+/+ mice with female Apc+/+M‑Lyslys+/+ mice. 
Furthermore, ApcMin/+ and Apc+/+mice on the M‑Lyslys‑EGFP/+ 
background were obtained by mating male ApcMin/+M‑Lyslys+/+ 
mice with female Apc+/+M‑lys lys‑EGFP/lys‑EGFP mice. The 
offspring were genotyped for Apc and M‑lys at ~30 days of age 
by PCR analysis of genomic DNA (18,19).
Resident peritoneal cell, splenic and intestinal tissue collec‑
tion. Each mouse was sacrificed between 30 and 138 days of 
age for experiments described below by cervical dislocation, 
immediately after which the peritoneal cavity was opened and 
peritoneal mononuclear cells (when required) were obtained 
by lavage with sterile phosphate buffer saline (PBS) at room 
temperature (25˚C), prior to dissection of the spleen or whole 
intestine. Splenic and intestinal tissues were collected in 
ice cold PBS, then stored in ice cold PBS for ≤5 min until 
processed as described in subsequent sections.
Intestinal adenoma count. Following lavage for peritoneal 
cells and dissection of the spleen, intestine was removed 
from the pylorus to the anus. The small intestine was then 
separated from the caecum and colon. Intestines were flushed 
out gently with PBS until no luminal content remained, after 
which they were carefully cut and opened out longitudinally 
to avoid adenoma disruption. For five ApcMin/+M‑Lyslys‑EGFP/+ 
at 92±23 days of age, adenomas were counted by naked eye 
examination of small intestinal tissue.
Histology. Tissue from the small intestine and spleen of three 
pairs of Apc+/+M‑Lyslys‑EGFP/+ and ApcMin/+M‑Lyslys‑EGFP/+ mice 
at 93±23 days of age underwent histological evaluation and 
immunohistochemistry for EGFP localisation as described 
below. Tissue from an SW480 human CRC xenograft trans‑
fected with an EGFP‑expressing herpes saimiri viral vector 
served as positive control due to previously demonstrated EGFP 
expression (20). Tissue from age matched ApcMin/+M‑Lyslys+/+ 
mice served as negative control. Sections were fixed in 
4% (w/v) paraformaldehyde in PBS for 6 h at 25˚C and paraffin 
wax embedded. Sections were cut to 5‑7‑µm thickness and 
underwent haematoxylin and eosin staining or immunohis‑
tochemistry (as described in the next section). Sections were 
viewed using fluorescence and phase contrast microscopy by 
a NIKON Eclipse E1000 fluorescence microscope (Nikon 
Corporation). Images were then captured using LUCIA GF 
imaging software (version 4.60) (Nikon Corporation).
Immunohistochemistry for the detection of EGFP. Steps of 
the procedure were performed at room temperature (25˚C) 
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except otherwise stated. Sections were de‑waxed progressively 
in xylene for 1 min each three times, then absolute (100%) 
ethanol for a minute each (x3), then washed in distilled water 
before endogenous tissue peroxidase activity was blocked by 
immersion of slides in 2% (v/v) H2O2 in absolute methanol for 
15 min. Subsequently, slides were washed in distilled water for 
10 min. Immunohistochemical staining of intestinal sections 
was carried out as previously described (21). Serum block 
was with 1.5% (v/v) goat serum (Dako; Agilent Technologies, 
Inc.) in PBS for 30 min. Sections were then incubated with 
rabbit anti‑Aquorea anti‑EGFP primary antibody (1:4,000; 
cat. no. A‑6455; Invitrogen; Thermo Fisher Scientific, Inc.) for 
20 h at 4˚C, after which slides were washed in PBS four times 
for 5 min each. Sections were then incubated for 30 min with 
HRP/dextran polymer‑conjugated goat anti‑rabbit secondary 
antibody (ready to use; cat. no. K4002; Dako; Agilent 
Technologies, Inc.) at room temperature. Subsequently, sections 
were washed in PBS four times for 5 min each. Sections were 
then incubated for 10 min with 0.1% (v/v) diaminobenzidine 
solution [Dako; Agilent Technologies, Inc.) in Tris‑buffer 
(0.05 M Tris (pH 7.6 with HCl)], containing 0.03% (v/v) 
H2O2 at room temperature. Sections were washed in tap 
water four times for 5 min each, counterstained with Mayer's 
Haematoxylin (cat no. MHS32; Sigma‑Aldrich; Merck KGaA) 
for 90 sec at room temperature, followed by immersion in 
Scott's tap water (0.167 M and MgS04 and 0.042 M NaHCO3 in 
distilled water) for 1 min. Slides were then rinsed in distilled 
water and the stained sections were dehydrated by immersion 
in absolute ethanol for 3 min three times, then immersed in 
xylene for three times 3 min each followed by mounting in 
DPX mountant (cat. no. 100579; Millipore Sigma). Sections 
were, viewed and images were captured as aforementioned.
Isolation and enumeration of small intestinal lamina propria 
mononuclear cells. Utilizing Apc+/+ M‑Lys+/+ mice as controls, 
intestinal LPMNCs were isolated from ApcMin/+ M‑Lys+/+ 
mice at the following ages: Weaning (~30 days of age; n=4 
pairs), prior to the appearance of macroscopically visible 
adenomas (~70 days of age; n=8 pairs), prior to death from 
macroscopic adenoma burden (~100 days of age; n=8 pairs). 
LPMNCs were isolated from mouse small intestine at room 
temperature (25˚C) with viability and numbers determined 
as previously described (22,23) ensuring complete enzymatic 
digestion of the intestines of mice at different ages.
Flow cytometric analysis of small intestinal lamina propria 
mononuclear cells. Flow cytometric analysis of small intes‑
tinal LPMNCs has been described previously for EGFP, 
phycoerythrin (PE) and propidium iodide (PI) expression (23). 
Flow cytometry was performed at room temperature (25˚C) on 
intestinal LPMNCs of six Apc+/+M‑Lyslys‑EGFP/+ mice and seven 
ApcMin/+M‑Lyslys‑EGFP/+mice at 74±2 days of age. Monoclonal 
primary antibodies utilized were as follows: F4/80 (1:100; 
cat. no. MCA497G; clone A3‑1; BioRad Laboratories, Inc.), 
BMDM‑1, ER‑HR3 (1:10), ER‑MP23, ER‑MP58, ER‑TR9, 
MOMA‑1 (all 1:10) and MOMA‑2. Antibodies (with the exclu‑
sion of F4/80) were hybridoma‑conditioned supernatant, a 
kind gift from Professor Pieter Leenen (24). A PE‑conjugated 
goat anti‑rat antibody was utilised (cat no. 305009; Bio‑Rad 
Laboratories, Inc.) at 1: 100 dilution. Cells were then washed 
in 10% foetal calf serum (FCS) labelled with propidium iodide 
(cat. no. P4864; Sigma‑Aldrich; Merck KGaA) at 1:2000 dilu‑
tion. Flow cytometry was performed using 5x104 LPMNCs and 
a FACS Vantage cytometer (Becton‑Dickinson and Company) 
with Cell Quest™ software version 3.3 (Becton‑Dickinson 
and Company). The R1 gate was set up to exclude PI‑positive 
cells and cells with low forward scatter (deemed non‑viable). 
EGFP‑positive cells (fluorescence level greater than that 
obtained by <0.1% of wild‑type LPMNCs) and macrophage 
marker positive cells ([M] with fluorescence level greater 
than that obtained by <0.1% of cells with non‑specific label‑
ling by control rat IgG) were analysed as expressing the 
relevant marker. Some cells were labelled with a cocktail of 
ER‑HR3, F4/80 and MOMA‑1 primary antibodies defined 
as the ‘Mac‑mix’(at the same concentration as utilized for 
single markers). BMDM‑1, ER‑MP23, ER‑MP58, ER‑TR9 
and MOMA‑2 were not evaluated further, due to the level 
of expression of undiluted hybridoma supernatant being no 
higher than for control rat IgG (data not shown).
Isolation of resident peritoneal cells. Lavaged perito‑
neal cells from three pairs of Apc+/+M‑Lyslys‑EGFP/+ and 
ApcMin/+M‑Lyslys‑EGFP/+ mice at 93±23 days were treated with 
5 mM EDTA in Hank's Balanced Salt Solution (Invitrogen; 
Thermo Fisher Scientific, Inc.) for 75 min and collage‑
nase/dispase enzymes for 90 min at 37˚C as for small intestinal 
LPMNCs (23). Peritoneal cells were then washed twice in an 
excess of 10% (v/v) foetal calf serum in PBS and re‑suspended 
at 25˚C in the same culture medium as for LPMNCs prior to 
been viewed by fluorescence microscopy.
Statistical analysis. The mean ± standard error of mean (SEM) 
was calculated for numbers or proportions of cells belonging to 
different small intestinal LPMNC sub‑populations of different 
groups of mice. Analysis of the difference between total 
LPMNCs of the oldest and youngest mice of either genotype 
(parametric data) was compared using unpaired two‑tailed 
Student's t‑tests. Statistical comparison of the myelomono‑
cytic sub‑population and adenoma numbers between mice was 
conducted using two‑tailed Mann‑Whitney U tests. Statistical 
analysis utilized Minitab software version 13 (Minitab, LLC). 
P≤0.05 was considered to indicate a statistically significant 
difference.
Results
Small intestinal LPMNC numbers decrease with age in 
ApcMin/+ mice. Initially, the total small intestinal LPMNC popu‑
lation was characterised during intestinal tumorigenesis in the 
ApcMin/+ mouse. It was determined if there were any differ‑
ences in small intestinal LPMNC numbers with age. There 
were no significant differences in LPMNC viability between 
groups of mice (Table I). There was no significant difference 
in total intestinal LPMNC numbers with age in Apc+/+ mice 
(33±1 vs. 109±2 days old; P=0.35), though older mice had a 
trend to reduced total LPMNCs (Table I). By contrast, total 
intestinal LPMNCs numbers significantly reduced with age in 
ApcMin/+ mice (33±1 vs. 109±2 days old; P=0.05; Table I). This 
suggested significantly reduced intestinal LPMNCs with age 
in ApcMin/+ mice.
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No significant effect of M‑lys hemizygosity on ApcMin/+ mouse 
small intestinal tumorigenesis. A previous study reported no 
difference in the proportion of EGFP‑expressing cells in the blood 
and bone marrow of Apc+/+M‑Lyslys‑EGFP/lys‑EGFP compared with 
Apc+/+M‑Lyslys‑EGFP/+ mice (18). Therefore, Apc+/+ and ApcMin/+ 
mice were bred onto the M‑Lyslys‑EGFP/+ background to facilitate 
the study of MM cell populations with intact M‑Lys function. It 
was determined if there was any impact of heterozygous M‑Lys 
deletion on intestinal tumorigenesis by counting macroscopic 
adenomas from ApcMin/+M‑Lyslys‑EGFP/+ intestine. Adenoma 
numbers were 45.8±10 (mean ± SEM; n=5) from the small 
intestine of ApcMin/+M‑Lyslys‑EGFP/+ mice (data not shown), similar 
to that of ApcMin/+M‑Lys+/+ mice previously bred in our facility 
that had 53±4 tumours (mean ± SEM; n=25) (25). Consequently, 
hemizygous deletion of M‑Lys appeared not to have significant 
impact on intestinal tumorignenesis in the ApcMin/+ mouse.
EGFP fluorescence in isolated small intestinal LPMNCs of 
M‑Lyslys‑EGFP/+ mice. M‑Lys mRNA expression has previously 
been demonstrated in mouse intestine (26). The presence of 
EGFP protein was tested for and fluorescence in isolated intes‑
tinal LPMNCs of M‑Lyslys‑EGFP/+ mice. EGFP fluorescence in 
intestinal LPMNCs of Apc+/+M‑Lyslys‑EGFP/+ mice in situ as well 
as in the LPMNC isolate was observed (Fig. S1).
Figure 1. Localisation of EGFP expression in Apc+/+ M‑lyslys‑EGFP/+ and ApcMin/+ M‑lyslys‑EGFP/+ mouse spleen. Sections of the spleen of an Apc+/+ M‑lyslys‑EGFP/+ 
mouse and an age‑matched ApcMin/+ M‑lyslys‑EGFP/+ mouse at 138 days of age were labelled with an antibody to EGFP (brown cells). Brown staining in (A) an 
EGFP‑expressing SW480 cell line, (B) the spleen of an Apc+/+ M‑lyslys‑EGFP/+ mouse and (C) the spleen of an ApcMin/+ M‑lyslys‑EGFP/+ mouse. In sections with 
omission of the primary antibody, absence of brown staining in (D) EGFP‑expressing SW480 cell line, (E) the spleen of an Apc+/+ M‑lyslys‑EGFP/+ mouse and 
(F) the spleen of an ApcMin/+ M‑lyslys‑EGFP/+ mouse. (G) Absence of brown staining in a section from the spleen of an ApcMin/+ M‑lys+/+ mouse. Arrows point to 
EGFP‑expressing cells. Scale bars, 100 µm. APC, adenomatous polyposis coli; EGFP, enhanced green fluorescent protein; M‑lys, mouse lysozyme.





Age, (days) LPMNCs, x106 Viability, % LPMNCs, x106 Viability, %
33±1 25.0±6.0 81.5±2.1 23.2±13.9 81.3±4.3
71±1 17.1±2.6 78.2±1.9 12.3±2.4 77.1±2.4
109±2 18.7±3.3a 76.8±1.6 10.6±2.4b 76.1±1.5
aP=0.35 vs. Apc+/+ mice at 33±1 days of age; bP=0.05 vs. ApcMin/+ mice at 33±1 days of age.
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EGFP expression in the spleen and small intestine of 
Apc+/+M‑Lyslys‑EGFP/+ and ApcMin/+M‑Lyslys‑EGFP/+ mice. Utilizing 
an EGFP‑expressing SW480 human CRC xenograft as positive 
control, it was determined if there was any difference in the resi‑
dent intestinal MM cell localization between Apc+/+M‑Lyslys‑EGFP/+ 
and ApcMin/+M‑Lyslys‑EGFP/+ mice at ~100 days of age (n=3 pairs) 
by immunohistochemistry for EGFP (Figs. 1 and 2). The spleen 
was studied as independent lymphoid tissue with a sentinel MM 
cell population. Even though there was some fibrotic distortion 
of ApcMin/+M‑Lyslys‑EGFP/+ splenic tissue, EGFP‑expressing cells 
were localized to the marginal zone of the spleen in both types 
of mice (Fig. 1B and C). In the intestine, EGFP‑expressing cells 
were localized to intestinal villi and in particular lymphoid 
follicles of Apc+/+M‑Lyslys‑EGFP/+ mice (Fig. 2Aa‑c). While 
EGFP‑expressing cells were also localized to the intestinal 
villi of ApcMin/+M‑Lyslys‑EGFP/+ mice and the periphery of 
adenomas, lymphoid follicles were absent from the intestine 
of ApcMin/+M‑Lyslys‑EGFP/+ mice (Fig. 2Ba‑c). This suggested 
loss of myelomonocytic cells and immune cell aggregates in 
ApcMin/+M‑Lyslys‑EGFP/+ mouse intestine
Figure 2. Localisation of EGFP expressing cells in Apc+/+ M‑lyslys‑EGFP/+ mouse small intestine. (A) Sections of the small intestine of an Apc+/+ M‑lyslys‑EGFP/+ 
mouse at 138 days of age labelled with an antibody to EGFP (brown cells). With the primary antibody to EGFP, brown staining in (a) proximal small intestine of 
the Apc+/+ M‑lyslys‑EGFP/+ mouse, (b) distal small intestine of the Apc+/+ M‑lyslys‑EGFP/+ mouse and (c) an intestinal lymphoid follicle of the distal small intestine of 
an Apc+/+ M‑lyslys‑EGFP/+ mouse (higher magnification, x600). In sections with omission of the primary antibody, absence of brown staining in (d) proximal small 
intestine and (e and f) distal small intestine. (g) Absence of brown staining in distal small intestine of an Apc+/+ M‑lys+/+ mouse stained with the EGFP antibody. 
(B) Sections of the distal small intestine of an ApcMin/+ M‑lyslys‑EGFP/+ mouse labelled with an antibody to EGFP. With the primary antibody to EGFP, brown 
staining in (a) LPMNCs within the villi and lamina propria of an ApcMin/+ M‑lyslys‑EGFP/+ mouse, (b and c) LPMNCs within an intestinal adenoma of an ApcMin/+ 
M‑lyslys‑EGFP/+ mouse. Inset are EGFP‑expressing cells within intestinal adenomas, shown at higher magnification (magnification, x600). In sections with omis‑
sion of the primary antibody, absence of brown staining in (d) distal small intestine and (e and f) adenomas. Arrows point to EGFP‑expressing cells. Scale bars, 
100 µm. APC, adenomatous polyposis coli; EGFP, enhanced green fluorescent protein; LPMNCs, lamina propria mononuclear cells; M‑lys, mouse lysozyme.
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Small intestinal myelomonocytic sub‑populations of 
Apc+/+M‑Lyslys‑EGFP/+ and ApcMin/+M‑Lyslys‑EGFP/+ mice. To deter‑
mine any differences in the intestinal MM population during 
the early stages of intestinal tumorigenesis, mice were studied at 
~70 days of age, which is prior to overt ApcMin/+ mouse lymphoid 
atrophy (7). This was also prior to ulceration, bleeding and 
potential secondary inflammation associated with advanced 
intestinal adenomas (6). As for mice on the M‑Lys+/+ background, 
there was a trend towards reduced total intestinal LPMNCs in 
ApcMin/+M‑Lyslys‑EGFP/+ mice which did not reach statistical signifi‑
cance (2.65±0.23x107 Apc+/+M‑Lyslys‑EGFP/+ vs. 1.72±0.39x107 
ApcMin/+M‑Lyslys‑EGFP/+ mice, P=0.12) Typical flow cytometry 
plots are shown in Fig. 3. There was no significant difference in 
the proportion of cells in the R1gate ([%] Apc+/+ 35. 40±4.00 vs 
ApcMin/+ 38.00±4.60, P=0.52). Data on the three expressed macro‑
phage marker antibodies, their mixture (Mac mix) and EGFP 
are displayed for Apc+/+M‑Lyslys‑EGFP/+ and ApcMin/+M‑Lyslys‑EGFP/+ 
mice (Table II). A higher proportion of LPMNCs from Apc+/+ 
M‑Lyslys‑EGFP/+ mice (n=6) expressed EGFP (P=0.11), ER‑HR3 
(P=0.11) or the Mac mix (P=0.18) compared with ApcMin/+ 
M‑Lyslys‑EGFP/+ littermates (n=7) (Table II). However, these differ‑
ences were not statistically significant.
Lower numbers of small intestinal myelomonocytic cells in 
the ApcMin/+M‑Lyslys‑EGFP/+ mice with the lowest total small 
Figure 3. Macrophage marker flow cytometry on M‑lyslys‑EGFP/+ intestinal LPMNCs. Representative flow cytometry plots from Apc+/+ M‑lyslys‑EGFP/+ mouse 
intestinal LPMNCs. Figures show the percentage of the total population of LPMNCs in relevant regions. EGFP fluorescence is on the abscissa, while PE 
fluorescence for macrophage markers is on the ordinate. R1, viable cell gate (not shown); R2, G+M+; R3, G+M‑; R4, G‑M‑; R5, G‑M+; R6, LPMNCs that 
do not express EGFP, but were labelled by the macrophage surface marker at a similar level to non‑specific rat IgG; R7, LPMNCs that expressed EGFP and 
were labelled by macrophage surface markers at a similar level to non‑specific rat IgG. LPMNCs, lamina propria mononuclear cells; M‑lys, mouse lysozyme; 
PE, phycoerythrin; G+, EGFP‑positive LPMNCs, G‑: EGFP‑negative LPMNCs. M+, LPMNCs labelled by macrophage markers above levels of non‑specific 
binding by rat IgG. M‑, LPMNCs not labelled by macrophage markers
Table II. Small intestinal myelomonocytic cell populations 
of ApcMin/+ M‑Lyslys‑EGFP/+ and Apc+/+ M‑Lyslys‑EGFP/+ mice at 
74±2 days of age.
Myelomonocytic
cell marker Apc+/+ ApcMin/+ P‑value
EGFP (M‑lys) 4.29±0.68 2.90±0.47 0.11
ERHR‑3
  G‑ 0.11±0.03 0.13±0.04 0.83
  G+ 1.02±0.25 0.55±0.13 0.23
F4/80
  G‑ 0.22±0.17 0.31±0.18 0.52
  G+ 0.24±0.10 0.14±0.07 0.20
MOMA‑1
  G‑ 0.04±0.01 0.07±0.02 0.12
  G+ 0.13±0.09 0.04±0.01 0.39
MAC‑MIX
  G‑ 0.16±0.10 0.15±0.05 0.48
  G+ 1.20±0.34 0.66±0.18 0.28
Pre‑immune rat IgG served as the antibody‑isotype control. 
G+, EGFP‑positive LPMNCs; G, EGFP‑negative LPMNCs.
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intestinal LPMNC numbers. To clarify if there was an asso‑
ciation between the trend to reduced ApcMin/+ total intestinal 
LPMNC and MM cell numbers, the lamina propria MM 
cell population of mice with the lowest total LPMNC yield 
were studied (ApcMin/+M‑Lyslys‑EGFP/+; mice nos. 4, 5 and 7; 
Tables SI and SII). These three mice had an LPMNC yield 
<35% compared with the average LPMNC yield of Apc+/+ 
mice. For these three ApcMin/+M‑Lyslys‑EGFP/+ mice, the propor‑
tion of EGFP‑expressing cells (1.78±0.26) was >2‑fold 
depleted compared with the mean for Apc+/+ mice (P=0.05) 
while the proportion of Mac‑mix expressing cells (0.37±0.04) 
was ~4‑fold depleted compared with the mean for Apc+/+ 
mice (P=0.05). This suggested that there was depletion of 
the myelomonocytic sub‑population associated with reduced 
intestinal LPMNCs.
Discussion
Selective EGFP fluorescence of MM cells without significant 
impact on tumorigenesis in the novel ApcMin/+M‑Lyslys‑EGFP/+ 
mouse in the present study prompted investigation into the 
MM cell population. No pan‑myelomonocytic cell marker has 
yet been fully validated for the murine MM cell population, 
which the present observation of EGFP‑negative Mac mix 
expressing cells corroborates. While a range of myelomono‑
cytic cell markers were used in the present study, rare subsets 
not evaluated in the present study should not be ignored. 
However, the murine M‑lys‑expressing MM sub‑population 
has been ascribed roles in phagocytosis and antigen presenta‑
tion in the intestinal micro‑environment, which are crucial to 
the immune response (27). A notable observation of the current 
study was a reduction in the ApcMin/+ lamina propria MM cell 
population early during intestinal adenoma development, 
associated with loss of intestinal lymphoid/MM cell aggre‑
gates but with retention of splenic marginal zone MM cells. 
It is possible that similar to the reduction in total intestinal 
LPMNC numbers observed, MM cell depletion is progres‑
sive through adenoma development. Conventional dendritic 
cells that function as antigen presenting cells in the intestinal 
micro‑environment are known to reside in intestinal lymphoid 
follicles (28). Consequently, the loss of lymphoid/MM cell 
interaction during intestinal adenoma development could 
impair the development of an immune response to tumour 
antigens, as previously shown in an autochthonous melanoma 
model (16), thus compromising immunosurveillance to prevent 
adenoma growth. In this respect, the prognosis following 
resection of early CRC is positively correlated with the extent 
of intra‑tumoral lymphocytic infiltration (29). Furthermore, 
response to PD‑1‑inhibition in melanoma is associated with 
the presence of a primed peri‑tumoral cytotoxic lymphocyte 
population (15).
ApcMin/+ mice ≤84 days of age did not have evidence of 
reduced peripheral MM cells or lymphocytes (8). Consequently, 
total intestinal lamina propria and intestinal MM cell deple‑
tion in 70‑day old ApcMin/+ mice appeared to be due to factors 
in the intestinal micro‑environment. After weaning in mice, 
F4/80‑positive resident intestinal macrophages of embryonic 
origin are now known to be replaced by F4/80‑negative macro‑
phages, which are constantly re‑populated from the peripheral 
circulation and adopt an anti‑inflammatory phenotype in the 
intestinal microenvironment (30,31). We previously demon‑
strated that the resident intestinal MM population is the 
highest PGE2‑secreting intestinal LPMNC sub‑population in 
mice. Furthermore, there is a trend for higher PGE2 produc‑
tion by the ApcMin/+ mouse resident intestinal MM population 
compared with the Apc+/+ mouse (23). PGE2 has previously 
been ascribed an immunosuppressive role (32,33), which would 
be consistent with an anti‑inflammatory MM cell phenotype. 
It is noteworthy that MM cell conversion to an immunosup‑
pressive phenotype has been shown to take up to 96 h after 
MM cell migration into the intestinal micro‑environment; 
with dendritic cells typically surviving for several days while 
macrophages typically survive for several weeks (28,34). 
Consequently, in this respect, enhanced Wnt signalling may 
be physiologically relevant to signal exclusion of MM cells 
prior to their conversion to an immunosuppressive phenotype 
in the ApcMin/+ intestinal milieu. However, other factors, such 
as cyclooxygenase‑2 (35), TGF‑β and T regulatory cells (36) 
may play a role in MM cell depletion from the intestinal 
micro‑environment.
Out of the murine macrophage surface markers evaluated 
in the present study, ER‑HR3 was the most widely expressed 
by intestinal lamina propria macrophages, irrespective of Apc 
genotype. ER‑HR3 is known to be expressed by a sub‑set of 
peripheral and resident tissue macrophages including those 
in sentinels, such as the skin, spleen and lymph nodes (37). 
Functionally, ER‑HR3‑expressing macrophages have been 
shown to be phagocytic and associated with immune latent 
milieu, such as the granulomata of BCG infected mice and 
with the relative exclusion of F4/80‑expressing macrophages, 
which are more common in other murine tissue (38).
In conclusion, the present study demonstrated that the loss 
of MM/lymphoid interaction occurs during the early stages of 
ApcMin/+ intestinal tumorigenesis, which may be due to enhanced 
micro‑environmental Wnt signalling. Subsequent anergy 
to emerging tumour neoantigens could compromise tumour 
immunosurveillance in the ApcMin/+ model. The relevance of 
this to colorectal adenomas and cancer requires evaluation, 
as well as the possibility that, similar to advanced melanoma, 
immune changes secondary to enhanced Wnt signalling may 
persist in MMR‑proficient CRC. Furthermore, the mechanism 
to MM cell depletion requires further evaluation. Such studies 
may contribute to understanding the resistance to CKI therapy 
of MMR‑proficient CRC despite a tendency for higher neoan‑
tigen burden compared with other malignancies, such as renal 
or bladder cancer (14).
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